EVLO Profile — Evelo Biosciences Inc
Evelo Biosciences is discovering and developing a class of medicines that are intended to act on cells in the small intestine to produce therapeutic effects throughout the body. The target cells in the small intestine play a role in governing human immune, metabolic and neurologic systems. Co.'s product candidates are orally delivered pharmaceutical preparations of naturally occurring, specific single strains of microbes or microbial extracellular vesicles. Co.'s product candidate, EDP1815, is being developed for the treatment of inflammatory diseases. Additional product candidates in development include EDP1867 and EDP2939 for the treatment of inflammatory disease.
|
|
Free EVLO Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Hold (2.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |